MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas

Cancer Research

Volumn 72, Issue 19, 2012, Pages 5060-5068

  Walls, Gerard V ^a   Lemos, Manuel C ^a   Javid, Mahsa ^a   Bazan Peregrino, Miriam ^b   Jeyabalan, Jeshmi ^a   Reed, Anita A C ^a   Harding, Brian ^a   Tyler, Damian J ^b   Stuckey, Daniel J ^b   Piret, Sian ^a   Christie, Paul T ^a   Ansorge, Olaf ^b   Clarke, Kieran ^b   Seymour, Len ^b   Thakker, Rajesh V ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BROXURIDINE; COMPLEMENTARY DNA; METHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER MORTALITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GENE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEN1 GENE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ADENOMA; ADENOVIRIDAE; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PITUITARY GLAND; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 84867125363     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1821     Document Type: Article

References (50)

1. Thakker RV. Multiple endocrine neoplasia type 1. In:De Groot JL, Jameson LJ, editors. Endocrinology. Philadelphia: Saunders Elsevier; 2010. p. 2719-41.
2. Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 2003;253:599-605. (Pubitemid 36649091)
3. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. Epub 2012 Jun 20.
4. Jensen RT. Management of the Zollinger-Ellison syndrome in patients withmultiple endocrine neoplasia type1. J InternMed 1998;243:477-88. (Pubitemid 28312244)
5. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:87-109. (Pubitemid 46421901)
6. Scherubl H, Jensen RT, Cadiot G, Stolzel U, Kloppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 2011;3:133-9.
7. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008;32:534-43. (Pubitemid 351458295)
8. Gsponer J, De Tribolet N, Deruaz JP, Janzer R, Uske A, Mirimanoff RO, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999;78:236-69. (Pubitemid 29343202)
9. Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary 2008;11:63-70. (Pubitemid 351168086)
10. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001;8:287-305. (Pubitemid 34019376)
11. Qu X, Wang M, Wang G, Han T, Mou C, Han L, et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 2011;164:499-504.
12. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008;158:11-8. (Pubitemid 351211035)
13. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7. (Pubitemid 18083554)
14. Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, et al.Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989;321:218-24. (Pubitemid 19187162)
15. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008;29:22-32.
16. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 2012;482:542-6.
17. Kim YS, Burns AL, Goldsmith PK, Heppner C, Park SY, Chandrasekharappa SC, et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999;18:5936-42. (Pubitemid 29520449)
18. Sayo Y, Murao K, Imachi H, Cao WM, Sato M, Dobashi H, et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 2002;143:2437-40. (Pubitemid 34521590)
19. Schnepp RW, Mao H, Sykes SM, Zong WX, Silva A, La P, et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004;279:10685-91. (Pubitemid 38372681)
20. La P, Yang Y, Karnik SK, Silva AC, Schnepp RW, Kim SK, et al. Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1. J Biol Chem 2007;282:31332-40. (Pubitemid 350044893)
21. Wang Y, Ozawa A, Zaman S, Prasad NB, Chandrasekharappa SC, Agarwal SK, et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res 2011;71:371-82.
22. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011;11:241-58.
23. McMenamin MM. Translational benefits of gene therapy to date. Clin Oncol Cancer Res 2011;8:10-15.
24. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32.
25. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, et al. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 2011;17:7174-82.
26. Vachani A, Moon E, Wakeam E, Haas AR, Sterman DH, Albelda SM. Gene therapy for lung neoplasms. Clin Chest Med 2011;32:865-85.
27. Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004;10:3634-8. (Pubitemid 39619282)
28. Thomas SM, Grandis JR. The current state of head and neck cancer gene therapy. Hum Gene Ther 2009;20:1565-75.
29. Harding B, Lemos MC, Reed AA, Walls GV, Jeyabalan J, Bowl MR, et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer 2009;16:1313-27.
30. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes 2005;54:2557-67. (Pubitemid 41233576)
31. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
32. Sambrook J RD. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001.
33. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963;17:299-313.
34. Xu J. Preparation, culture and immortalization of mouse embryonice fibroblasts. In:Sons JW, editor. Current protocols in molecular biology. Somerset (NJ): John Wiley and Sons; 2005.
35. Qi X, Chang Z, Song J, Gao G, Shen Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs 2011;22:556-62.
36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
37. Gunkel M, Erdel F, Rippe K, Lemmer P, Kaufmann R, Hormann C, et al. Dual color localization microscopy of cellular nanostructures. Biotechnol J 2009;4:927-38.
38. Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-44. (Pubitemid 28110764)
39. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-83. (Pubitemid 27308405)
40. +/- mice. Nat Med 1996;2:1316-21.
41. Bertolino P, TongWM,Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003;17:1880-92. (Pubitemid 37072302)
42. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A 2001;98:1118-23. (Pubitemid 32121196)
43. Loffler KA, Biondi CA, Gartside M, Waring P, Stark M, Serewko-Auret MM, et al. Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer 2007;120:259-67. (Pubitemid 44956834)
44. Hussein N, Casse H, Fontaniere S, Morera AM, Asensio MJ, Bakeli S, et al. Reconstituted expression of menin in Men1-deficient mouse Leydig tumour cells induces cell cycle arrest and apoptosis. Eur J Cancer 2007;43:402-14. (Pubitemid 46138041)
45. Cavallari I, Silic-Benussi M, Rende F, Martines A, Fogar P, Basso D, et al. Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma. Genes Chromosomes Cancer 2009;48:383-96.
46. Stalberg P, Grimfjard P, Santesson M, Zhou Y, Lindberg D, Gobl A, et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004;89:2326-37. (Pubitemid 38619871)
47. Wu TL, Ertl HC. Immune barriers to successful gene therapy. Trends Mol Med 2009;15:32-9.
48. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006;6:215-26.
49. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97:7482-7. (Pubitemid 30431489)
50. Davis JR, McMahon RF, Lowenstein PR, Castro MG, Lincoln GA, McNeilly AS. Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis. J Endocrinol 2002;173:265-71. (Pubitemid 34552455)